Outpace Bio Announces $144 Million Oversubscribed Series B

Seattle – August 1, 2024 – Cooley advised Outpace Bio, a cell therapy company using unrivaled artificial intelligence-powered protein design to program immune cells for improved function inside patients battling solid tumors, on its $144 million oversubscribed Series B financing. Outpace will use the proceeds from the financing to advance multiple programmed T-cell product candidates to early clinical proof of concept for the treatment of solid tumors and to support the expansion of its future pipeline leveraging its powerful plug-and-play technology platform.

Partner Colleen Badgley led the Cooley team advising Outpace.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.